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Abstract
Background: To evaluate local control and cosmetic outcome in patients with cancer in the nasal cavity/vestibule
treated with intensity-modulated radiotherapy (IMRT).
Methods: From 06/2008 – 11/2012 15 consecutive patients presenting nasal cavity (n=5), ala of the nose (n=5)
or nasal vestibule tumors (n=5) were treated in our institution either postoperatively (n=8) or as definitive treatment
(n=7).
Results: Mean/median follow-up (FU) was 30/22 months (range 17-62). Two patients suffered from a local
relapse. As a salvage therapy an ablatio nasi was carried out in curative intention in both patients. Thereafter no
failure was reported. Local control rate, ultimate local control and overall survival after 2 years were 87%, 100% and
100%, respectively. None of the patients developed grade II or higher late sequels. Cosmetic outcome after RT was
very satisfying so far.
Conclusion: IMRT for nasal tumors is effective and well tolerated. Radical surgical procedures can be saved for
curative salvage treatment.
Keywords: Nasal tumors; IMRT; SIB-IMRT; Definitive
radiotherapy; Cosmetic outcome
Introduction
Tumors of the nasal cavity or of the nasal vestibule are rare [1].
Optimal treatment depends on tumor size, tumor expansion and nodal
status and includes definitive or postoperative radiotherapy, or surgery
alone. Surgical removal often implies complex reconstruction which
may end in disfiguring results and consecutively essential impairment
of quality of life. Radiation therapy (RT) can be carried out as external
beam or brachytherapy, with good local control rates of 67-92% after 5
years [2-6].
Recently, few single center study groups presented retrospective
data on treating patients with sinunasal cancer with intensity
modulated radiotherapy (IMRT). They revealed excellent local control
rates with minimized toxicity [7-12]. In those series only a minority of
included patients were diagnosed with nasal cavity or nasal vestibule
tumors. Cosmetic outcomes were therefore not evaluated.
The goal of the present study was to show effectiveness of IMRT in
a single center series of a homogeneous patient collective with nasal
tumors in terms of local control and cosmetic outcome.
Patients and Methods
From 06/2008 to 11/2012 15 consecutive patients presenting with
histologically proven squamous cell cancer (SCC, n=13) or
adenocarcinoma (n=2) were treated in our institution with IMRT
either postoperatively after tumor excision (n=8) or as definitive
treatment (n=7).
Patient and treatment parameters are summarized in Table 1. One
patient had ipsilateral lymph node metastases (N1). In this case a neck
dissection was carried out prior to IMRT.
The dose was normalized to the mean dose in planning target
volume (PTV) 1. For intensity optimization, the prescribed dose
encompassed at least 95% of the PTV. Simultaneously integrated boost
(SIB) was used delivering two-three different dose levels in the same
treatment session.
Target volumes were delineated as follows: GTV included the gross
extent of primary disease, taking clinical and radiological findings into
account; PTV1 was defined by adding 10-15 mm margin to the GTV,
dependent on the GTV proximity to critical structures eye, optical
nerve); PTV2 covered areas considered at high risk for potential
microscopic disease. No elective lymph node irradiation was carried
out. Mean GTV volume was 12.4 ccm (range: 2.9-27.9 ccm).
Mean age (years) 58 (range: 28-78)
Gender
Male
Female
12 (80%)
3 (20%)
RT sequence
Postoperative IMRT
Definitive IMRT
8 (54%)
7 (46%)
Histology 13 (87%)
Nuclear Medicine & Radiation
Therapy Janssen S, et al., J Nucl Med Radiat Ther 2014,5:1http://dx.doi.org/10.4172/2155-9619.1000170
Research Article Open Access
J Nucl Med Radiat Ther Cancer Radiation Therapy ISSN:2155-9619 JNMRT, an open access journal
SCC
adenocarcinoma
2 (13%)
Location
nasal cavity
vestibule
ala of the nose
5 (33.3%)
5 (33.3%)
5 (33.3%)
RT doses
(5 fractions/week)
35x2=70 Gy
34x2=68Gy
33x2=66 Gy
32x2=64 Gy
31x2=62Gy
6 (40%)
2 (13%)
5 (33%)
1 (7%)
1 (7%)
N-status
T1
T2
T3
T4
N1
N2
N3
N4
2 (13%)
10 (66%)
1 (7%)
2 (13%)
1
0
0
0
Cisplatin or cetuximab concomitant 8 (54%)
Table 1: Patient and treatment related characteristics.
Mean dose to the left and right lacrimal glands was 2.9 Gy (range:
0.5-9.3 Gy), and 2.6 Gy (range: 0.5-7 Gy). The maximal lens dose was
6.6 Gy (range: 3.7-11.6 Gy) and 6.5 Gy (range: 1.9-13.3 Gy) on the
right and left side, respectively. Dose to the lacrimal sac/proximal
nasolacrimal duct was estimated and summed up to a mean value of
25 Gy (range: 3-58) on the right side and 29 Gy (range: 2-56) on the
left.
To ensure sufficient dose delivery to the skin close to GTVs, bolus
material (0.5.1 cm thickness) was used in all patients (Figure 2). Nasal
tamponade was used in all patients, to reduce/avoid build up effect.
Irradiation was delivered with three to seven coplanar beam angles by
a 6-MV dynamic MLC system (Varian Medical Systems, Palo Alto,
CA) using sliding window technique, or using volumetric modulated
arc technique (VMAT, since 04/2010). Patients were immobilized
from head to shoulders using a commercially available thermoplastic
mask in supine position.
Regular FU visits were carried out in our joint clinic at the
Department of Otorhinolaryngology, Head and Neck Surgery.
Institutional standards for patient assessment included physical
examination approximately every 2 months in the first year of follow-
up, every three months in the second to third year and every 6 months
in the fourth to fifth year. Last FU and grading of toxicity (CTCAE
grading system) was performed personally or by phone calling (SJ or
GS in 08-09/13).
Systemic Therapy
Regular FU visits were carried out in our joint clinic at the
Department of Otorhinolaryngology, Head and Neck Surgery.
Institutional standards for patient assessment included physical
examination approximately every 2 months in the first year of follow-
up, every three months in the second to third year and every 6 months
in the fourth to fifth year. Last FU and grading of toxicity (CTCAE
grading system) was performed personally or by phone calling (SJ or
GS in 08-09/13).
Systemic therapy preferably consisted of cisplatin (40 mg/m2
weekly) and was switched to cetuximab in case of cisplatin related
adverse effects (cetuximab loading dose: 400 mg/m2 followed by
weekly applications of 250 mg/m2 referring to Bonner et al. [13]). For
patients with contraindications against cisplatin, cetuximab was
favored primarily. The indication for systemic therapy was based on
tumor stage, resection status, age and Karnofsky performance score. 8
patients presenting with T4 tumors, N1 or R1 resection received
systemic therapy. Cisplatin was started in 6 patients, a switch to
cetuximab was carried out in four patients after 2 (n=3) and 4 (n=1)
courses due to tinnitus (n=3) or rising levels of creatinine (n=1). In
two patients with contraindications against cisplatin, cetuximab was
preferred as first choice.
Statistics
Statistical calculation was performed using the statistic program
implemented in Stat View (Version 4.5; SAS Institute, Cary, NC).
Results
Outcome
Mean/median FU was 30/22 months (range 17-62). Median local
control, ultimate local control and overall survival after 2 years was
87% (Figure 1), 100% and 100%, respectively. Two patients developed
a loco-regional relapse after 6 and 10 months, respectively. One of
those patients was treated with definitive RT; one had an excision
before RT. Ablatio nasi was carried out in both cases as successful
salvage therapy revealing no recurrence up to now 7 and 26 months
later, respectively.
Figure 1: Kaplan Meier curve of local control rate.
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Late term effects
No grade II or higher late sequels were seen during the FU time so
far. 12/13 organ preserved tumor free patients suffered from a mild to
moderate dryness of the nasal mucosa which was tolerable under
symptomatic therapy (Table 3). One patient described a repetitive
grade 2 epistaxis, one patient a grade 1 epistaxis. In consequence to the
low doses to the lacrimal glands and lenses mentioned in the methods
section no severe late adverse effect concerning the lacrimal glands or
vision is expected. No nasolacrimal stenosis occurred in any patient.
Cosmetic results
At the time of last visit each patient was asked to evaluate the
cosmetic results of RT using a scale from 1-5 in which 1 would stand
for no satisfaction with respect to cosmetic outcome and 5 for high
satisfaction with the cosmetic outcome comparable with status before
initial diagnosis and treatment. Patients rated cosmetic outcome either
as excellent (grade 5, 9/13) or as good (grade 4, 4/13). Table 2
summarizes the results for each patient. In Figures 2-7 exemplary
photographs demonstrate objective outcome related to the isodose
plans of patients who underwent definitive IMRT.
Patients
(n)
Nasal
tumors (%)
Definitive RT (%) RT technique RT dose (Gy)
(Dose/fraction)
CTx
(%)
LC (%) OS (%) Cosmetic
results
Katz 2002 78 62 60 Anterior and
lateral fields
68 (1.8 or 1.2 twice
daily)
1 60 (5yrs) 50 (5yrs) n.a.
Langendijk
et al. [4]
56 100 100 Opposed lateral
6MV fields +/-
BT boost
67.5 (2.5) 0 80 (2yrs) 66 (2yrs) n.a.
Levendag
et al. [6]
64 100 78 BT 44 (3 twice daily) 0 92 (5yrs) 59 (5yrs) 65% excellent
or good results
(n=23)
Wallace et
al. [2]
71 100 89 Anterior field
MV elektrons
and 6MV,
BT
65-75 3 87 (5yrs) 76(5yrs) n.a.for def.
treatment, poor
for 6 patients
and good for 2
patients treated
with surgery and
RT
Agger et al.
[14]
174 100 69 Opposed lateral
fields 250KV or
MV
54 (3)
62-66 (2)
0 67 (5yrs) 50 (5yrs) n.a.
Total 443 92 79 1 77 60
Table 3: Summary of studies on conventionally treated patients with nasal cancer published in the IMRT era (not treated with IMRT). BT:
Brachytherapy; n.a.: not assessed
c RT sequence T stage Tumor site RT dose Patients’ satisfaction with
cosmesis *
Late sequels
1 definitive 2 ala 70 ablatio dry nasal mucosa grade I
2 definitive 2 vestibule 70 5 none
3 definitive 2 nasal cavity 70 5 Intermittent epistaxis,
dry nasal mucosa grade I
4 definitive 4 vestibule 68 5 dry nasal mucosa grade I
5 definitive 2 nasal cavity 68 5 dry nasal mucosa grade I
6 definitive 2 ala 70 5 dry nasal mucosa grade I
7 definitive 2 nasal cavity 70 4 dry nasal mucosa grade I
8 postoperative 4 vestibule 66 ablatio dry nasal mucosa grade I
9 postoperative 1 ala 66 5 dry nasal mucosa grade I
10 postoperative 2 nasal cavity 66 5 dry nasal mucosa grade I
11 postoperative 3 vestibule 62 5 dry nasal mucosa grade I, intermittent
epistaxis
Citation: Janssen S, Glanzmann C, Holzmann D, Studer G (2014) IMRT for Nasal Tumors – Local Control and Cosmetic Outcome. J Nucl Med
Radiat Ther 5: 170. doi:10.4172/2155-9619.1000170
Page 3 of 7
J Nucl Med Radiat Ther Cancer Radiation Therapy ISSN:2155-9619 JNMRT, an open access journal
12 postoperative 2 ala 66 4 slightly olfactory impairment, dry
nasal mucosa grade I
13 postoperative 2 ala 66 4 dry nasal mucosa grade I
14 postoperative 2 nasal cavity 64 5 dry nasal mucosa grade I
15 postoperative 1 vestibule 70 4 dry nasal mucosa grade I
Table 2: Summary of cosmetic outcome and late sequels for each patient (CTCAE grade 1=asymptomatic mucosal crusting, grade 2: interfering
with airflow, grade 3: significant nasal obstruction)
*Cosmetic outcome in self-assessment using a 5 point scale
(“1”=poor cosmetic outcome, “5”=very satisfying)
Systemic therapy
No late sequels were observed concerning systemic therapy.
Figure 2: 55 year old patient, vestibule nasi tumor T2N0, GTV
volume: 2.9 ccm, 70 Gy.
 
Figure 3: 56 year old patient, cavum nasi tumor T2N1, GTV
volume: 13.2 ccm, 70 Gy
Figure 4: 66 year old patient, vestibule nasi tumor T4N0, GTV
volume: 6.8 ccm, 68 Gy
Figure 5: 67 year old patient, cavum nasi tumor T2N0, GTV
volume: 9.5 ccm, 68G y
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Figure 6: 69 year old patient, ala nasi tumor T2N0, GTV volume:
27.9 ccm, 70 Gy.
 
Discussion
We evaluated clinical outcome and early cosmetic results in a
patient group presenting with exclusively nasal tumors treated with
IMRT.
In historic series on cohorts treating nasal vestibule tumors with
conventional RT or brachytherapy, local control and overall survival
rates range from 67% to 92% and 50% to 90%, respectively [2,4,6,14].
The largest series of the DAHANCA study group including 174
patients with nasal vestibule cancer reports a local control rate and an
overall survival rate of 67% and 50% at 5 years, respectively [14] (Table
3). In the latter series RT was delivered in opposed lateral fields (KV or
MV) or with an anterior electron field +/- brachytherapy boost. Doses
range from 54 Gy in 3 Gy single doses to 62-69 Gy in 2 Gy or 2.5 Gy
doses [2,4,14]. Langendijk et al. observed rhinorrhoe in 45%, nasal
dryness in 39% and epistaxis in 15% of the patients as late toxicity (4).
Radiation induced necrosis of the skin was seen in 3 patients. Wallace
et al. showed severe late term complications requiring hospitalization
and/or surgical intervention in 3 out of 8 postoperatively treated
patients. 21% of patients treated with RT only experienced
complications which resolved without intervention [2].
Figure 7: 78 year old patient, vestibule nasi tumor T2N0, GTV
volume: 20.2 ccm, 70 Gy.
 
IMRT is effective to deliver high doses to target volumes while
limiting the dose to adjacent critical structures [12]. We found 7 other
single center retrospective studies reporting comparable local control
(49-87%) and overall survival data of 45-100% at 2-5 years with low
rate of toxicity in patients with sinunasal cancer [7-12,15]. Most IMRT
series did not observe any grade 3 visual impairment [8-11]. In
contrast to the above mentioned series with conventional RT
techniques, those IMRT series included mostly paranasal cavity
tumors with different histologies ranging from SCC to
esthesioneuroblastoma, adenoidcystic carcinoma and sarcomas. Only
a small number of patients with nasal cavity/nasal vestibule tumors
were included (Table 4). No published IMRT series evaluating patients
with nasal cancer exclusively could be found.
Furthermore most of the patients were treated postoperatively.
Definitive treatment was carried out in only 9% - 21% in the collectives
of Wiegner, Duprez and Madani, respectively while other reports
assessed series with only postoperatively treated patients [9-11].
In contrast we had half the cases treated with definitive IMRT. Our
results of local control and overall survival are comparable with the
large series of conventional treated patients as well as the
heterogeneous group treated with IMRT. For our small sample size,
disease control was identical for postoperative and definitive IMRT.
Cosmetic outcomes were not evaluated in any of the other IMRT
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studies. Wallace et al. treating nasal vestibule cancer patients with
conventional RT only report of “poor” cosmetic results in 6 patients
and “good” cosmetic results in 2 patients treated with surgery and RT
[2]. Levendag et al. evaluated cosmetic outcome consequently in
patients with early-stage nasal vestibule cancer treated with
brachytherapy. They scored cosmetic results using a 3 point scale. 65%
showed good or excellent objective results judged by an external panel
[6]. We used a five point scale in order to further differentiate
outcome. Furthermore, we did not assemble an external panel to
evaluate cosmetic outcome; cosmetic results as presenting at last visit
of the patients treated with 70Gy are shown in Figure 2. Altogether
cosmetic outcome is very satisfying with only grade 4 and 5 in self-
assessment standing for good and excellent outcomes.
Patients with
sinunasal
tumors
(n)
Nasal tumors (%) Definitive RT
(%)
RT technique RT dose
(Dose/
fraction) (Gy)
CTx
(%)
LC (%) OS (%) Cosmetic
results
Combs et al.
[9]
46 16/46 (35) 0 IMRT 64 (2) 0 49 (3yrs) 90 (3yrs) n.a.
Daly et al.
[10]
36 7/36 (19) 0 IMRT 70 (2.12) 17 58 (5yrs) 45 (5yrs) n.a.
Hoppe et al.
[15]
85 24/85 (28) 0 IMRT in 35% 50-70 (1.8-2) 2 87 (5yrs) 67 (5yrs) n.a.
Madani et al.
[7]
84 16/84 (19) 11 IMRT 70 (2) 0 71 (5yrs) 59 (5yrs) n.a.
Dirix et al.
[11]
40 6/40 (15) 0 IMRT 60/66 (2) 0 76 (2yrs) 89 (2yrs) n.a.
Duprez et al.
[8]
130 31/130 (24) 22 IMRT 70 (2) 5 59 (5yrs) 52 (5yrs) n.a.
Wiegner et al.
[12]
52 11/52 (21) 9 IMRT 66 (2.2) 56 74 (2yrs) 66 (2yrs) n.a.
Present study 15 15/15 (100) 47 IMRT 53 87 (2yrs) 100 (2yrs) 69% excellent,
31% good
Total 488 126 11 17 70 71
Table 4: Summary of series including all sinunasal tumor sites treated with IMRT, no separate analysis of outcome in patients with nasal tumors,
n.a. = not assessed.
Larger studies including nasal tumors executively are mostly not
applying chemotherapy [2,4,6,14]. IMRT studies dealing with a
heterogeneous patient collective including paranasal sinus cancers
were applying systemic therapy in 0 to and 17% [7-11,15]. Wiegner et
al. applied chemotherapy in a sub collective of patients with nasal
cancer in 36% [12]. In our study collective systemic therapy was given
in 54%.
Even our study collective is small and the FU is short, to our
knowledge this is the first study evaluating cosmetic outcomes in
patients with nasal tumors treated with IMRT.
Conclusion
SIB-IMRT in patients presenting with nasal cancer is effective in
terms of local control and overall survival either postoperatively after
tumor excision or as definitive organ sparing IMRT. Early cosmetic
outcomes were subjectively as well as objectively very satisfying.
Ablatio nasi can be saved for curative salvage therapy.
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